References
- Bendandi M. Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma. Expert Rev. Anticancer Then: 1, 65–72 (2001).
- Kwak LW, Campbell MJ, Czerwinski DK et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J. Med 327, 1209–1215 (1992).
- ••The first ever demonstration that humanscan be immunized against their own tumor antigens.
- Hsu FJ, Caspar CB, Czerwinski D et al Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma — long-term results of a clinical trial. Blood 89,3129–3135 (1997).
- •The series of patients immunized with idiotype vaccines featuring the longest follow-up.
- Bendandi M, Gocke CD, Kobrin CB et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nature Med. 5, 1171–1177 (1999).
- ••A Phase II clinical trial featuring the firstdemonstration of vaccine-induced molecular remissions.
- Neelapu SS, Gause BL, Nikcevich DA et al. Vaccine therapy of follicular lymphoma in first remission: long-term follow-up of Phase II results and high-rate of chemotherapy-induced complete remissions in a controlled, randomized Phase III trial. Proceedings of the 45th Annual Meeting of the American Society of Hematology San Diego, USA Abs 4953 (2003).
- Carroll WL, Thielemans K, Dilley J, Levy R. Mouse x human heterohybridomas as fusion partners with human B-cell tumors. J. Immunol Methods 89,61–72 (1986).
- Timmerman JM, Czerwinski DK, van Beckhoven A et al A Phase I/II trial to evaluate the immunogenicity of recombinant idiotype protein vaccines for the treatment of non-Hodgkin's lymphoma (NHL). Proceedings of the 42"th Annual Meeting of the American Society of Hematology San Francisco, USA Abs 2481 (2000).
- King CA, Spellerberg MB, Zhu D et aL DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nature Med 4, 1281–1286 (1998).
- Hawkins RE, Russell SJ, Marcus R et al A pilot study of idiotypic vaccination for follicular B-cell lymphoma using a genetic approach. CRC NO: 92/33. Protocol NO: PH1/027. Hum. Gene Ther. 8,1287-1299 (1997).
- Timmerman JM, Singh G, Hermanson G et al. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res. 62,5845–5852 (2002).
- McCarthy H, Ottensmeier CH, Hamblin T, Stevenson FK. Anti-idiotype vaccines. Br. Haematol. 123,770–781 (2003).
- Spellerberg MB, Zhu D, Thompsett A et al. DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C. J. Immunol. 159, 1885–1892 (1997).
- Inoges S, Rodriguez-Calvillo M, Lopez-Diaz de Cerio A et al. Feasibility of idiotype vaccination in relapsed B-cell malignancies. Haematologica 88,1438–1440 (2003).
- •A study comparing hybridoma-based idiotype vaccine feasibility in five different types of lymphoma in first relapse.
- Freedman AS, Neuberg D, Mauch P et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Haematologica 84\(Supp1.1), 41–43 (1999).
- Leonard JP, Vose J, Timmerman JM et al. Recombinant idiotype-KLH vaccination (MyVaxTm) following CHOP chemotherapy in mantle cell lymphoma. Proceedings of the 45th Annual Meeting of the American Society of Hematology San Diego, USA Abs 357 (2003).
- Wilson WH, Neelapu SS, Rosenwald A et al Idiotype vaccine and dose-adjusted EPOCH-Ritmdmab treatment in untreated mantle cell lymphoma: preliminary report on clinical outcome and analysis of immune response. Proceedings of the 45th Annual Meeting of the American Socieoz of Hematology San Diego, USA Abs. 358 (2003).
- Massaia M, Borrione P, Battaglio S et al Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood 94, 673–683 (1999).
- Coscia M, Mariani S, Battaglio S et al Long- term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. Leukemia 18, 139–145 (2004).
- Osterborg A, Yi Q, Henriksson L et al Idiotype immunization combined with granulocyte macrophage colony-stimulating factor in myeloma patients induced Type I, major histocomaptibility-restricted, CD8- and CD4- specific T-cell responses. Blood 91, 2459–2466 (1998).
- Rasmussen T, Hansson L, Osterborg A et al. Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B-cells. Blood 101, 4607–4610 (2003).
- Kwak LW, Taub DD, Duffey PL et al Transfer of myeloma idiotype-specific immunity from an actively immunized marrow donor. Lancet 345, 1016–1020 (1995).
- Cabrera R, Diaz-Espada F, Barrios Y et al Infusion of lymphocytes obtained from a donor immunised with the paraprotein idiotype as a treatment in a relapsed myeloma. Bone Marrow Transplant. 25, 1105–1108 (2000).
- Kwak LW, Neelapu SS, Bishop MR. Adoptive immunotherapy with antigen-specific T-cells in myeloma: a model of tumor-specific donor lymphocyte infusion. Semin. Oncol. 31, 37–46 (2004).
- National Institutes of Health website; information on clinical research in human volunteers. www.dinicaltrials.gov Accessed 10th February, 2004.
Websites
- Genitope corporation website: www.genitope.com Accessed 12th February, 2004.
- Favrille Corporation website, clinical development stage company www.favrille.com Accessed 15th February, 2004.